- Home
- HQI vs BDTX Comparison
HQI vs BDTX Comparison
Compare HQI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- BDTX
- Stock Information
- Founded
- HQI 2002
- BDTX 2014
- Country
- HQI United States
- BDTX United States
- Employees
- HQI N/A
- BDTX N/A
- Industry
- HQI Professional Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- BDTX Health Care
- Exchange
- HQI Nasdaq
- BDTX Nasdaq
- Market Cap
- HQI 143.3M
- BDTX 132.5M
- IPO Year
- HQI N/A
- BDTX 2020
- Fundamental
- Price
- HQI $10.03
- BDTX $2.87
- Analyst Decision
- HQI Strong Buy
- BDTX Strong Buy
- Analyst Count
- HQI 2
- BDTX 6
- Target Price
- HQI $16.00
- BDTX $14.83
- AVG Volume (30 Days)
- HQI 14.9K
- BDTX 1.2M
- Earning Date
- HQI 08-07-2025
- BDTX 08-05-2025
- Dividend Yield
- HQI 2.34%
- BDTX N/A
- EPS Growth
- HQI N/A
- BDTX N/A
- EPS
- HQI 0.24
- BDTX 0.09
- Revenue
- HQI $33,651,000.00
- BDTX $70,000,000.00
- Revenue This Year
- HQI N/A
- BDTX N/A
- Revenue Next Year
- HQI $4.99
- BDTX N/A
- P/E Ratio
- HQI $38.53
- BDTX $32.58
- Revenue Growth
- HQI N/A
- BDTX N/A
- 52 Week Low
- HQI $9.04
- BDTX $1.20
- 52 Week High
- HQI $15.75
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- HQI 47.95
- BDTX 68.91
- Support Level
- HQI $10.20
- BDTX $2.43
- Resistance Level
- HQI $10.41
- BDTX $2.72
- Average True Range (ATR)
- HQI 0.20
- BDTX 0.18
- MACD
- HQI 0.02
- BDTX 0.02
- Stochastic Oscillator
- HQI 39.68
- BDTX 99.31
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.